The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More
News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW. This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition. The top stories: … Read More
Digital lung ‘twins’ could help predict the efficacy of inhaled drugs in patients with respiratory problems. Healthcare company Ebenbuild has developed lung digital twin technology, which uses patient-specific models to predict drug deposition. According to a study published in Nature Communications Medicine, the validated technology… Read More
Michael Eyres, Lead Scientist at the Medicines Discovery Catapult (MDC), explores how spatial epigenetics can accelerate biomarker drug discovery. Epigenetics, once seen… Read More
An innovative drug developed to treat idiopathic pulmonary fibrosis (IPF) will now be evaluated as a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). CS014, a HDAC inhibitor developed by biotech company Cereno Scientific, will be studied as a treatment for PH-ILD to address a… Read More
The US Food and Drug Administration (FDA) has approved Boehringer’s Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). Jascayd is an oral treatment option for adult patients with IPF, becoming the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B)… Read More
Calluna Pharma will use Qureight’s AI-powered imaging and clinical data curation platform to support its Phase II AURORA study. Qureight will analyse imaging data from adult patients, evaluating anatomical lung changes in individuals treated with CAL101, Calluna’s lead asset for the treatment of idiopathic pulmonary fibrosis (IPF). Read More
PureTech Health has announced the launch of a new founded entity Celea Therapeutics to deliver therapies for serious respiratory diseases. Its lead programme, deupirfenidone (LYT-100), is a Phase III-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for… Read More
Trevi Therapeutics has announced positive topline results from its Phase IIb CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all… Read More
Biopharmaceutical company Rein Therapeutics and core imaging laboratory Qureight have announced plans to collaborate on an idiopathic pulmonary fibrosis (IPF) clinical trial. The companies will integrate Qureight’s deep-learning platform into Rein’s planned Phase II trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide. … Read More
Qureight and biopharmaceutical company Remedy Cell have agreed a partnership to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF). The primary objective of the RC-0315 Phase Ib clinical study is to measure drug safety and tolerability. The study’s exploratory objectives will assess the… Read More
Insilico Medicine reports improvement in patients with idiopathic pulmonary fibrosis (IPF) in a Phase IIa trial of ISM001-055. The drug, developed using generative AI, targets TNIK (Traf2- and NCK- interacting kinase) for the treatment of IPF. The topline results demonstrate that ISM001-055 is… Read More
Insilico Medicine has shared positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055, a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase). The drug was designed utilising generative AI to treat idiopathic pulmonary fibrosis (IPF). The study met both its primary… Read More
Insilico Medicine has completed patient enrolment in a Phase IIa study in China, which is investigating the safety, tolerability, and preliminary efficacy of AI-designed TNIK inhibitor INS018_055 for idiopathic pulmonary fibrosis (IPF). The randomised, double-blind, placebo-controlled study is being conducted across 29 clinical centres in China… Read More
A therapeutic candidate which operates through a novel mRNA biology mechanism of action could open new avenues for treating idiopathic pulmonary fibrosis (IPF) patients. Anima Biotech has identified a preclinical candidate, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts. By inhibiting myofibroblasts’… Read More
New Phase IIa data indicates that Vicore Pharma’s C21 has the potential to transform the treatment of idiopathic pulmonary fibrosis (IPF) and restore lung function. In data from the AIR trial, C21 has demonstrated long-term efficacy. At 36 weeks, the average forced vital capacity (FVC) had… Read More
